Vizex Investments Ltd
financial consultations

Last news

Long term recommendation - Immune Pharmaceuticals (NASDAQ.IMNP)

Feb 04, 2018 35
Febryary 4th. We are starting coverage…

Transenterix completely sold the rights on the Surgibot

Dec 18, 2017 36
December 18th 2017. Transenterix…

FDA approves Transenterix Senhance robot for commercial sales in the U.S.

October 14th. TransEnterix, Inc. (NYSE American: TRXC), a medical device company that is pioneering the use of robotics to improve minimally invasive surgery, today announced the Company has received FDA 510(k) clearance for the Senhance™ Surgical Robotic System. With this clearance, the Senhance becomes the first new market entrant into the field of abdominal surgical robotics since 2000. The approval opens the way for Transenterix to the biggest robotic surgery market - the U.S. And the company along with Intuitive Surgical became the second major player on the global market.

Вайзекс Инвестментс ООД © 2015 | Всички права запазени